Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

VanEck Vectors Pharmaceutical ETF (PPH)

59.75
Delayed Data
As of 3:59pm ET
 -1.25 / -2.05%
Today’s Change
45.23
Today|||52-Week Range
70.01
-8.51%
Year-to-Date

Investment Objective

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors  US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Pharmaceutical Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

No recent news for VanEck Vectors Pharmaceutical ETF.

Performance

1 month-0.23% 3 years+10.93%
3 months+7.20% 5 years--
1 year-9.52% Since inception+14.57%
Data through 08/24/2016

Quote Details

Previous close$61.00
Open day’s range59.64 – 61.29
Net asset value (NAV)61.00 (08/23/2016)
Daily volume197,480
Average volume (3 months)63,279
Data as of 3:59pm ET, 08/24/2016

Peer Comparisonvs. Health ETFs

 PPHCategory
Performance 5-yr return--+15.32%
Expense Gross exp ratio0.41%0.47%
Risk 5 year sharpe ratio--1.12
Net assets$268.2M$1.2B
Average market cap$69.5B$31.2B
Average P/E27.818.7
Dividend / Share--0.22%

Competitors

XLV Health Care Select Sector SPDR® Fund
RYH Guggenheim S&P 500® Equal Weight Health...
VHT Vanguard Health Care Index Fund ETF Shar...

Holdings

Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
JNJ Johnson & Johnson5.21%
ABBV AbbVie5.17%
GSK GlaxoSmithKline5.11%
PFE Pfizer5.04%
AZN AstraZeneca4.99%
ABT Abbott Laboratories4.99%
SNY Sanofi4.96%
NVS Novartis4.93%
BMY Bristol-Myers Squibb4.91%
MRK Merck4.90%

Partner Offers

Search for Jobs